Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Sarcoidosis as a multisystem inflammatory disorder

Rheumatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
High-risk extrapulmonary sarcoidosis

Syncope, high-grade heart block, ventricular arrhythmia, acute heart failure, visual loss, severe uveitis, seizure, myelopathy, pituitary crisis, severe hypercalcaemia or rapidly declining kidney function can cause sudden death or irreversible disability.

Action: Admit or arrange same-day organ-specific assessment, monitor rhythm and physiology, treat immediate cardiac, neurological, ocular or metabolic instability, obtain infection and malignancy samples where safe, and start specialist immunosuppression when the probability and threat justify action without waiting for a low-yield serum marker.

Synopsis

Recognise sarcoidosis beyond the chest, secure proportionate tissue and microbiological evidence, identify cardiac, neurological, ocular, renal and calcium threats, and coordinate organ-specific treatment without mistaking granulomas for a diagnosis.

  • Sarcoidosis is a diagnosis of compatible multisystem disease plus supportive histology when needed and exclusion of competing granulomatous causes; non-necrotising granulomas alone are not diagnostic.
  • Map lung, lymph node, skin, eye, heart, nervous system, calcium, kidney, liver, gland, joint and constitutional features at baseline rather than treating the chest film as the whole disease.
  • First safety priority is high-risk organ screening: ask about syncope, palpitations, visual loss and focal neurology, check ECG, calcium, renal and liver profiles and escalate abnormalities promptly.
  • A classic Löfgren pattern of bilateral hilar nodes, erythema nodosum and ankle periarthritis may not require biopsy after specialist review, while asymmetric or mass-like disease usually does.
  • Choose the safest informative tissue—skin, peripheral node or EBUS-guided thoracic node—and request microbiology and architecture as well as granuloma description.
  • Serum ACE is neither sensitive nor specific enough to confirm disease or direct treatment. A normal value does not exclude organ-threatening sarcoidosis.
  • Observe stable, low-risk disease actively. Treat to prevent irreversible organ injury or relieve material functional burden, not merely to normalise imaging.
  • Prednisolone is usual first-line systemic treatment; methotrexate is a common first steroid-sparing choice when prolonged therapy, relapse or toxicity makes glucocorticoid alone unsuitable.
  • Cardiac therapy includes rhythm monitoring, pacemaker or defibrillator decisions and heart-failure care alongside immune suppression; steroid response does not protect against scar-mediated arrhythmia.
  • Do not prescribe calcium or vitamin D reflexively: check calcium physiology and specialist advice because granulomas can generate excess calcitriol.

Key red flags

Syncope, presyncope, sustained palpitations, new conduction block or ventricular arrhythmia requires urgent cardiac monitoring and sarcoid-aware electrophysiology assessment.

Painful red photophobic eye, new floaters or reduced vision requires same-day ophthalmology because posterior or optic-nerve disease may be sight threatening.

Seizure, meningism, cranial neuropathy, focal weakness, myelopathy, altered consciousness or polyuria with hypernatraemia suggests neurosarcoidosis or pituitary involvement.

Severe thirst, vomiting, confusion, dehydration, nephrolithiasis, oliguria or marked calcium elevation requires urgent renal, fluid and cardiac assessment.

Haemoptysis, hypoxaemia, rapidly falling lung function or disproportionate dyspnoea raises infection, pulmonary embolism, pulmonary hypertension or fibrotic complication rather than a routine flare.

Bulky asymmetric nodes, a focal mass, profound weight loss, night sweats or progressive disease despite corticosteroid requires renewed malignancy and infection exclusion.

Cardiac involvement

Unexplained AV block in a younger adult, ventricular ectopy, syncope, ventricular tachycardia or non-ischaemic cardiomyopathy should trigger urgent cardiac-sarcoid assessment.

Neuroendocrine involvement

Cranial neuropathy, aseptic meningitic symptoms, seizures, myelopathy, hypothalamic dysfunction or diabetes insipidus can be the dominant presentation.

Investigation priorities

01
First-line organ safety screenFirst stepFirst line

Detect silent cardiac, metabolic, renal, hepatic and haematological involvement at diagnosis.

Management branches

First diagnostic sequenceMap organs, then obtain the safest proof

Clinical or imaging findings raise a new multisystem sarcoidosis possibility.

  1. Screen immediately for cardiac, eye, neurological, calcium and renal danger while documenting thoracic, skin, gland and musculoskeletal features.
  2. Review infection, malignancy, occupational exposure, medicine and immune-deficiency mimics and select the least invasive site that can distinguish them.
  3. Combine compatible pathology and organ pattern with negative targeted microbiology; record diagnostic confidence rather than calling every granuloma sarcoid.
High-risk organ escalationProtect function before routine staging

Syncope, arrhythmia, visual loss, central neurological disease, severe calcium disturbance or renal decline occurs.

  1. Admit or arrange same-day cardiac, ophthalmic, neurological or renal care and stabilise rhythm, vision, pressure, electrolytes and organ failure.
  2. Obtain rapid organ imaging and accessible tissue or cultures when feasible, but do not delay treatment of a probable sight-, life- or cord-threatening syndrome.
  3. Use specialist glucocorticoid induction plus early steroid-sparing therapy and add device, surgery or organ support that immune suppression cannot replace.

Key medicines

PrednisoloneFor clinically important systemic disease, start 20–40 mg orally each morning for four to six weeks, then taper against objective organ response toward 5–10 mg daily and withdrawal over roughly six to twelve months.Exclude infection and malignancy where possible; monitor glucose, blood pressure, mood, eyes, bone, infection and adrenal suppression and define a steroid-sparing threshold.
Methylprednisolone intravenous pulseFor selected sight-, cardiac-, neurological- or renal-threatening disease, give 500–1000 mg intravenously once daily for three days under organ-specialist supervision before an oral and steroid-sparing plan.Culture and treat infection, monitor rhythm, glucose, pressure, mental state and fluid, and avoid using a pulse to bypass uncertain diagnosis when tissue remains safely obtainable.
Open full textbook →Answer 2 questions
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • BTS clinical statement on pulmonary sarcoidosisUK diagnostic, multisystem screening, treatment and follow-up practice.
  • ERS clinical practice guideline on sarcoidosis treatmentOrgan-specific indications, glucocorticoid, steroid-sparing and biologic therapy.
  • Prednisolone UK product informationGlucocorticoid dose principles, contraindications and cumulative safety.
  • Methotrexate UK product informationOnce-weekly dosing and marrow, liver, kidney, lung and reproductive safety.
  • Hydroxychloroquine UK product informationDose, retinal, cardiac and neuromuscular cautions.
  • Infliximab UK product informationInfusion, TB, hepatitis, infection and heart-failure safety; sarcoidosis use is off-label.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draft
Ocular involvement

Photophobia, pain, floaters, reduced acuity, retinal symptoms or optic-disc change indicates uveal, retinal or optic disease with potential permanent sight loss.

Clinical stateAwaiting review
JurisdictionUnited Kingdom